Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Neuroscientific Biopharmaceuticals Ltd. (MSX) Share Price & Analysis

MSX Stock Chart & Stats

A$0.05-A$0.00(-5.66%)
At close: 11:00 AM GMT+11
AU$0.05AU$0.055AU$0.06AU$0.0653 Aug17 Aug1 Sep14 Sep28 Sep12 Oct26 Oct
Day’s Range
AUD 0.05 - AUD 0.05
52-Week Range
AUD 0.04 - AUD 0.18
Previous Close
AUD 0.05
Volume
N/A
Average Volume (3M)
101.92K
Market Cap
AUD 19.49M
Enterprise Value
AUD 15.52M
Total Cash (Recent Filing)
AUD 4.63M
Total Debt (Recent Filing)
AUD 87.04K
Price to Earnings (P/E)
―
Beta
0.52
Next Earnings
Mar 03, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Minimal debt and no prior-year debt reduce refinancing and interest-rate exposure, while sizable equity relative to assets provides a buffer for operations. This gives NSB more financial flexibility than a highly leveraged biotech, even as losses continue.

Defined Neuroscience Focus

Operating in neuroscience therapeutics gives NSB a clearly defined development and commercialization scope around neurological and neuropsychiatric conditions. A focused therapeutic remit can support concentrated expertise and prioritization, although the pack does not establish commercial traction.

Prior Cash Generation

Positive operating and free cash flow in 2024 shows the business has at least demonstrated the ability to generate cash in one period. Although later weakness makes this inconsistent, the prior result provides evidence that cash generation is not impossible.

Bears Say

Unstable Revenue Base

Revenue has been inconsistent, including zero revenue in 2022, 2025 and 2026, while the income statement describes no stable commercial base. This weakens visibility into recurring monetization and leaves the company dependent on development progress rather than an established revenue engine.

Persistent Operating Losses

NSB returned from a small 2024 profit to sizeable losses in 2025 and an even larger loss in 2026, with gross profit negative in most periods and EBIT/EBITDA deeply negative. This indicates that current spending is not supported by sustainable operating profitability.

Deteriorating Cash Burn

Operating cash flow is negative in most periods and worsened meaningfully in 2026 versus 2025; free cash flow was negative in several reported years. Continued burn reduces self-funding capacity and raises the likelihood that development plans require additional financing.

MSX FAQ

What was Neuroscientific Biopharmaceuticals Ltd.’s price range in the past 12 months?
Neuroscientific Biopharmaceuticals Ltd. lowest share price was AU$0.04 and its highest was AU$0.18 in the past 12 months.
What is Neuroscientific Biopharmaceuticals Ltd.’s market cap?
Neuroscientific Biopharmaceuticals Ltd.’s market cap is AU$19.49M.
When is Neuroscientific Biopharmaceuticals Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
Is Neuroscientific Biopharmaceuticals Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Neuroscientific Biopharmaceuticals Ltd. pay dividends?
Neuroscientific Biopharmaceuticals Ltd. does not currently pay dividends.
What is Neuroscientific Biopharmaceuticals Ltd.’s EPS estimate?
Neuroscientific Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neuroscientific Biopharmaceuticals Ltd. have?
Neuroscientific Biopharmaceuticals Ltd. has 389,718,540 shares outstanding.
Which hedge fund is a major shareholder of Neuroscientific Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:MSX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology